BiDil(R) Data to be Presented at Heart Failure Society of America Science Meeting.- Understanding of BiDil's Clinical Effects Broadens- LEXINGTON, Mass. -- NitroMed, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : NTMD), an emerging pharmaceutical company and the maker of BiDil([R]) (the fixed dose combination A fixed dose combination (FDC) is a formulation of two or more active ingredients combined in a single dosage form available in certain fixed doses. Fixed dose combination drug products may improve medication compliance by reducing the pill burden of patients. of isosorbide dinitrate/hydralazine hydrochloride hydrochloride /hy·dro·chlo·ride/ (-klor´id) a salt of hydrochloric acid. hy·dro·chlo·ride n. A compound resulting from the reaction of hydrochloric acid with an organic base. ), an orally administered medicine approved in the United States for the treatment of heart failure in self-identified black patients, said today that five abstracts will be presented at the 11th Annual Scientific Meeting of the Heart Failure Society of America taking place September 16-19, 2007 in Washington, DC. "This new information helps broaden our clinical understanding of BiDil by adding to the body of evidence that BiDil represents important adjunct therapy in the treatment of black heart failure patients. These latest data about BiDil's efficacy to improve survival in high risk heart failure patients with atrial fibrillation atrial fibrillation Irregular rhythm (arrhythmia) of contraction of the atria (upper heart chambers). The most common major arrhythmia, it may result as a consequence of increased fibrous tissue in the aging heart, of heart disease, or in association with severe infection. , its use in the elderly, its use with concomitant therapies, and the genetic results, expand our understanding of BiDil's effects in younger and aging patients with different concomitant diseases and heart failure medications," said Manuel Worcel, MD, NitroMed's Chief Medical Officer. The abstracts to be presented are: 1. Mitchell JE, Tam SW, Trivedi K, Sabolinski ML and Worcel M. Atrial Fibrillation and Mortality in Patients Enrolled in the African American African American Multiculture A person having origins in any of the black racial groups of Africa. See Race. Heart Failure Trial. HFSA HFSA Heart Failure Society of America (also seen as HFSOA) HFSA Hungarian Financial Supervisory Authority HFSA Health Flexible Spending Account HFSA Hispanic Faculty Staff Association HFSA Health Flexible Spending Arrangement 2007. 2. Taylor AL, Sabolinski ML, Tam SW, Worcel M, Cohn JN. Fixed-dose combined isosorbide dinitrate/hydralazine improves outcomes in elderly heart failure patients in the African-American Heart Failure Trial. HFSA 2007. 3. Ghali JK, Tam SW, Mitchell JE, Sabolinski ML, Worcel M. Role of Digitalis digitalis (dĭj'ĭtăl`ĭs), any of several chemically similar drugs used primarily to increase the force and rate of heart contractions, especially in damaged heart muscle. The effects of the drug were known as early as 1500 B.C. in the Contemporary Management of Systolic Heart Failure systolic heart failure Cardiology Heart failure with a severely reduced systolic function–LV ejection fraction of ≤35%. Cf Diastolic heart failure. in African Americans. HFSA 2007. 4. Rame EJ, Tam W, McNamara DM, Worcel M, Sabolinski ML, Dries DL. Prognostic Import of the Corin I555(P568) Allele allele (əlēl`): see genetics. allele Any one of two or more alternative forms of a gene that may occur alternatively at a given site on a chromosome. in African-Americans with Moderate to Severe Heart Failure: Results from the A-HeFT Trial. HFSA 2007. 5. Sardar Sardar, in some senses also Sirdar (Persian: سردار ) (Sardār MR, Kezerashvili A, Galvao M, Maybaum S, Trivedi K, Shin JJ. Optimization of Medical Therapy in African-American Patients with Heart Failure Referred for Cardiac Resynchronization Therapy. HFSA 2007 About NitroMed, Inc. NitroMed of Lexington, Massachusetts is an emerging pharmaceutical company and the maker of BiDil([R]) (isosorbide dinitrate/hydralazine hydrochloride), an orally administered medicine available in the United States for the treatment of heart failure in self-identified black patients. In this population, BiDil is indicated as an adjunct to current standard therapies such as angiotensin converting enzyme Noun 1. angiotensin converting enzyme - proteolytic enzyme that converts angiotensin I into angiotensin II angiotensin-converting enzyme, ACE peptidase, protease, proteinase, proteolytic enzyme - any enzyme that catalyzes the splitting of proteins into (ACE) inhibitors and beta blockers. There is little experience in patients with New York Heart Association Class IV heart failure. BiDil was approved by the U.S. Food and Drug Administration, primarily on the basis of efficacy data from the Company's landmark A-HeFT (African American Heart Failure Trial) clinical trial and is marketed by NitroMed through a specialty medicines sales organization. For full prescribing information, visit: www.BiDil.com. BiDil is a registered trademark of NitroMed, Inc. Forward Looking Statements Statements in this press release about future expectations, plans and prospects for the Company, including the Company's positioning to achieve the Company's goals and objectives, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks discussed in the Section titled "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007, which has been filed with the SEC, and in the other filings that the Company makes with the SEC from time to time. The forward-looking statements included in this press release represent the Company's views as of the date of this release. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion